in-PharmaTechnologist.com presents a very special round-up of the latest movers and shakers in the industry, including news from our very own Nick Taylor, as well as bulletins from BIA, Merrimack and PhRMA.
The BioIndustry Association (BIA) has appointed Steve Bates as CEO.
Previously, he was senior director of external affairs and market access at Genzyme UK and Ireland. He also boasts a 15-year career within the UK Government , as special advisor to John Reid MP in his time as Home Secretary.
, chairman Tim Edwards said: "Steve will work with BIA members to engage government on our policy initiatives, such as the citizens innovation fund, and to ensure that the UK’s Coalition Government delivers on the strategy for UK Life Sciences.”
in-PharmaTechnologist (IPT) deputy editor Nick Taylor will leave the editorial team this Friday.
A veteran reporter of the pharma and biotech industries, Taylor has worked his way up the ranks on both IPT and Outsourcing-Pharma.com for the past four years.
He is leaving to take a sabbatical, traveling around the world. He will remain a freelance pharmaceutical journalist as he goes.
The Pharmaceutical Research and Manufacturers of America (PhRMA) has drafted J&J and AstraZeneca honchos Joaquin Duato and Tony Zook onto its board of directors.
Duato is currently worldwide chairman of J&J’s (Johnson & Johnson) pharmaceuticals group, whilst Zook is executive VP of global commercial at Astra.
“We are pleased to welcome two industry veterans to PhRMA’s board of directors,” said president and CEO John Castellani.
“As we continue to advocate for innovation and patient-centred policies in the US and around the world, PhRMA and its membership will undoubtedly benefit from these leaders’ keen insights and deep knowledge of our sector.”
Eisai has promoted Shaji Procida from VP of finance to the role of VP and CFO.
She will now take charge of all the firm’s financial operations in the US, and will continue to serve as a member of the company’s executive committee.
Lonnel Coats, president, said: "Her expertise and business leadership will continue to ensure our company's financial wellbeing as well as support our on-going efforts to achieve our human health care mission of helping to improve the lives of patients and their families."
John Mendelsohn has joined the board at Merrimack Pharmaceuticals.
Once the president of The University of Texas Anderson Cancer Center, Mendelsohn still serves at the university as co-director of the new Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy.
"John's contributions to the advancement of cancer therapy and his vision for the future of predictive medicine in cancer care continue to break new ground," said Gary Crocker, chairman at Merrimack. "His expertise will be a tremendous asset to Merrimack as we advance our portfolio of eight oncology therapeutics and multiple diagnostics."